This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Antitrust litigation - Sandoz - RareGen - United Therapeutics Corporation - Smiths Medical ASD

Sandoz and RareGen filed a complaint accusing United Therapeutics Corporation and Smiths Medical ASD of impeding competition for the drug Remodulin from a new generic drug that treats pulmonary arterial hypertension. The complaint claims that to thwart the product launch and to maintain higher prices, the companies placed artificial restrictions on Smiths’ injection cartridges to ensure they can only be used to administer the brand-name treprostinil drug supplied by United Therapeutics.

To add details to this Case File regarding legal or economic representatives, please contact editors@mlex.com.

Timeline

Parties

Get the inside track, with MLex

With a global network of expert journalists digging deep into the areas of risk that matter to your business and clients—and the highest standards of impartiality—you can have complete trust in MLex to keep you ahead of the regulatory curve.


  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from specialists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

TRY MLEX FREE FOR 14 DAYS

View the parties now

Already a subscriber? Click here to login